NEW YORK, June 29, 2017 (GLOBE NEWSWIRE) -- Establishment Labs, a global medical device company focused on aesthetic technologies with a strong emphasis on product development and innovation, announced the addition of Alexandre Mendonça Munhoz, M.D., Ph.D., to the company’s Medical Advisory Board. The appointment was announced during the 37th Jornada Paulista de Cirurgia Plastica in São Paulo, Brazil simultaneously with the commercial launch of Motiva Implants® in Brazil.
“We are pleased to have Dr. Munhoz join our Medical Advisory Board,” said Juan José Chacón-Quirós, CEO and founder of Establishment Labs. “Our mission is made possible by bringing leading minds of the industry together to solve problems that have plagued breast aesthetic and reconstructive surgery for decades. Dr. Munhoz has been a leader in the pursuit of excellence in breast surgery, and as we expand into the world’s second largest market, we welcome a prominent member of the Brazilian school of Plastic Surgery to our Medical Advisory Board.”
Dr. Munhoz is currently a Professor of Plastic Surgery, Breast Surgery Division of Plastic Surgery at the University of São Paulo School of Medicine in São Paolo, Brazil, and is a full member of the Brazilian Society of Plastic Surgery (SBCP), which coordinates the Scientific Department in the São Paulo region. Dr. Munhoz participated as a guest member of the international consultants of Plastic and Reconstructive Surgery (PRS) and Breast Journal since 2006. In 2016, he assumed the position of Associate Editor of PRS-Global Open Journal. His achievements include 25 scientific awards related to plastic surgery research, 115 published scientific papers, with 81 indexed in PubMed platform and first author on 76 studies.
“Motiva Implants are truly innovative and are designed with cutting-edge research from the material science, incorporating advances and understanding from both the surface technology and physiology disciplines. For years, I have been searching for the solutions that Establishment Labs’ scientists have developed in the design of Motiva. Professor Scott Spear, an international leader in the field of plastic surgery, and one of my mentors in academic life, introduced me to their advances and technologies and I am grateful for the opportunity to join the Medical Advisory Board and continue to advance the work of my mentor,” said Dr. Munhoz. “I am excited to bring these state-of-the-art technologies and implants to the community of plastic surgeons and patients in Brazil.”
“We are thrilled to officially launch our Motiva Implants in Brazil, a key market in surgical aesthetics, during Jornada Paulista de Cirurgia Plastica," said Eddie De Oliveira, Latin America Vice President of Sales at Establishment Labs. "The excitement of plastic surgeons around the launch of our products is palpable, and we are humbled to see our science reach broad commercialization.”
About Establishment Labs
Establishment Labs is a global, privately held, medical technology company with a strong emphasis on innovation that designs, develops, manufactures and markets an innovative product portfolio. Its CE-marked Motiva Implants® line of silicone breast implants (http://www.motivaimplants.com) utilizes ultra-high purity medical-grade silicone and is subject to the strictest quality assurance testing throughout the manufacturing process. Motiva Implants® are sold in more than 60 countries worldwide. Puregraft®'s FDA cleared and CE-Marked technology provides plastic surgeons with purified fat for reinjection on the sterile field and is used in hospitals and clinics around the world. Divina® is a proprietary 3D imaging technology for full integration in consultation and surgical planning of unique solutions for breast aesthetics and reconstruction. All manufacturing facilities are fully compliant with both FDA and ISO applicable standards.
Contact Lynn Pieper Lewis or Leigh Salvo Gilmartin Group (415) 937-5404 email@example.com